EarningsQ2 2026 Earnings Report
MX:ABT Q2 2026 EPS Results
Actual EPS$23.70
Consensus EPS$23.11
Beat/MissBeat by +$0.60
One Year Ago EPS$22.80
MX:ABT Q2 2026 Revenue Results
Actual Revenue$227.87B
Expected Revenue$226.54B
Beat/MissBeat by +$1.33B
YoY Revenue Growth+13.02%
Earnings Announcement Details
QuarterQ2 2026
Date07/16/2026
TimeBefore Open
Conference CallThursday, July 16, 2026
MX:ABT Upcoming Earnings
Abbott Laboratories's next earnings date is estimated for October 21, 2026, based on past reporting schedules.
Q2 2026 Earnings Call Audio
MX:ABT Q2 2026 Earnings Call
0:00 / 0:00
Q2 2026 Earnings Slide Deck
Q2 2026 Earnings Call Summary
Earnings Call Sentiment|Positive
Overall, the call conveyed constructive momentum across Abbott’s diversified portfolio with multiple product and regulatory milestones, gross margin expansion, and raised EPS guidance. Key growth engines — diagnostics (notably cancer testing), nutrition recovery, devices (EP, rhythm management, heart failure) and diabetes/CGM — provide visibility to second-half acceleration. Offsetting risks include a soft respiratory season hurting rapid/molecular diagnostics, China VBP headwinds, structural heart US commercial execution needs, and uncertainty/timing around reimbursement and regulatory approvals for some high-impact products (e.g., CGM reimbursement expansion, Libre Duo FDA clearance). On balance, highlights notably outweigh the lowlights, with achievable near-term drivers and a clear pipeline cadence underpinning positive momentum.Company Guidance
Comparable Sales Growth and EPS Beat
Comparable sales increased 4.8% in Q2 2026 and adjusted EPS was $1.31, which exceeded the midpoint of guidance and consensus. Management reaffirmed full-year comparable sales guidance of 6.5%–7.5% and raised full-year adjusted EPS guidance to $5.45–$5.60.
Gross Margin Expansion
Adjusted gross margin improved to 58.0% of sales, a 100 basis point increase year-over-year, driven by favorable mix (including Exact Sciences contribution) and margin expansion initiatives.
Strong Diagnostics and Core Lab Trends
Core laboratory US business grew 7.5% in the quarter and diagnostic instrument-derived testing volumes were described as strong and stable, used as a forward-looking indicator of durable healthcare demand.
Cancer Diagnostics Momentum (Cologuard / Exact Sciences)
Cancer diagnostics grew 13% in Q2, driven by mid-teens growth of Cologuard and contributions from precision oncology and international expansion. Management expects stronger growth in H2 supported by care-gap programs and recently launched tests.
Nutrition Sequential Recovery and Market Leadership
Nutrition sales rose sequentially by $125 million. International pediatric nutrition returned to positive growth of 6.5% and US pediatric reflected full benefit of recent WIC contract wins, leading to market leadership in both WIC and non-WIC segments. Adult nutrition saw double-digit retail consumption gains vs. late-2025 exit after price actions.
EP and Cardiovascular Device Momentum
Medical devices grew 8.5% overall. Electrophysiology showed early acceleration with Bolt PFA catheter (Bolt 2.0) launched in the US in May and Bolt/Tactiflex Duo driving >20% growth in Europe. Rhythm management grew 9.5% and heart failure grew 9% (double-digit in the US). Management expects to begin outperforming the market in H2 and recapture share.
Diabetes Portfolio and New Product Regulatory Win
Continuous glucose monitoring sales exceeded $2 billion, up 9.5% in the quarter. Abbott received CE Mark for Libre Duo (dual glucose-ketone sensor) and plans international rollout in fall with a future US launch pending FDA approval.
Pipeline and Regulatory Milestones
Key pipeline achievements: completed enrollment in the coronary IVL pivotal trial, submitted FDA application for Amulet 360 left atrial appendage device, and CE Mark for Libre Duo. Management expects launches (Amulet 360, Libre Duo, tectiflex/bolt-related launches) and patient enrollment starts (balloon-expandable TAVR, leadless conduction pacing, Cephea mitral replacement, peripheral IVL, wearable lactate monitor) over next 12–24 months.
Positive FX and Quarterly Guidance
Foreign exchange had a favorable 0.8% year-over-year impact on Q2 sales and management expects FX to be +1% for the full year (with ~-1% impact in Q3). Q3 adjusted EPS guidance provided at $1.38–$1.46.
Operational & Integration Progress
Exact Sciences integration reportedly progressing smoothly and contributing to revenue/mix. Management expects cash generation and cash flow to be ahead of January forecasts, enabling greater capital return flexibility.
MX:ABT Earnings History
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed